-Wall Street Journal
I-Mab Reveals Promising Results in Phase 1b/2 Study for Advanced Non-Small Cell Lung Cancer Treatment
I-Mab (NASDAQ:IMAB) announced results from the Phase 1b/2 study of uliledlimab in combination with toripalimab (Tuoyi) in patients with…